Viacord Service Agreement

13. Oktober 2021

TORONTO, 28 years old. Oct. 2011 /PRNewswire/ — J. E. Davies, President and Chief Executive Officer of Tissue Regeneration Therapeutics (TRT), today announced an exclusive licensing agreement with Perkin`s Family Cord Blood Bank ViaCord® which will now offer U.S. families the ability to extract stem cells from the tissue that surrounds the vessels of the umbilical cord. a rich source of mesenchymal stem cells (MSCs). The proprietary extraction method is made possible by TRT technology for periivavascular navel cells (HUCPVC). ViaCord family cable banking services currently offer families the opportunity to obtain their baby`s umbilical cord blood and umbilical cord cells for possible medical use by the child or a family member. To date, ViaCord has retained the umbilical cord blood of more than 250,000 newborns. Canadian families have been the first in the world to have access to this CORD TISSUE HUCPVC technology since 2006 through a license from the CReATe Cord Blood Bank, which commercializes trt technology as PeristemTM, making TRT and CreATe leaders in the global stem cell community. „With this agreement between ViaCord and TRT, ViaCord can only offer U.S.

families the opportunity to benefit from TRT`s robust and cutting-edge technology, internationally patented,“ said Bruce Berckmans, Vice President of Business Development at TRT. TRT technology is available in the U.S. to ViaCord`s future parents in addition to their current Cord Cell banking services. „The agreement between ViaCord and TRT continues to characterize ViaCord`s leadership in the field of umbilical cord tissue stem cell banking by providing our customers with exclusive access to this abundant source of umbilical cord tissue MSCs,“ said Morey Kraus, Chief Scientific Officer of ViaCord. This new feature is exclusive to ViaCord, the only umbilical cord blood collection service in the United States with licenses for patent rights regarding the extension of umbilical tissue MSCs, as well as the extraction and extension of MSCs from tissues to umbilical cord vessels. Newborn umbilical tissue stem cell banks, in addition to umbilical cord blood stem cells, offer the potential for a greater number and diversity of cells, increase the chances of potential success and benefit from possible therapeutic applications. „ViaCord has forged a leading position in the study and identification of new applications for stem cell treatments in the clinical environment and is an ideal complement to the robust scientific foundation we have built at TRT in the MSC field,“ said Davies. . . .

  • Allgemein
  • Keine Kommentare

Kommentarfunktion ist deaktiviert.

Trackback URI |

Blog Top Liste - by ÖKOPORTAL - Das Webverzeichnis der Ökobranche  in der grünen Suchmaschine Blogverzeichnis - Blog Verzeichnis Blogverzeichnis - Blog Verzeichnis